{
    "organizations": [],
    "uuid": "b55973706ed7097351a5fa8dc3c1d30f86d5efaf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-prometic-life-sciences-q4-total-re/brief-prometic-life-sciences-q4-total-revenue-6-6-mln-vs-4-1-mln-idUSASC09U4D",
    "ord_in_thread": 0,
    "title": "BRIEF-Prometic Life Sciences Q4 Total Revenue $6.6 Mln Vs $4.1 Mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 28 (Reuters) - Prometic Life Sciences Inc:\n* PROMETIC REPORTS ITS Q4-2017 AND YE-2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON ACTIVITIES\n* ‍TOTAL REVENUES FOR Q4 ENDED DECEMBER 31, 2017 WERE $6.6 MILLION COMPARED TO $4.1 MILLION FOR Q4 ENDED DECEMBER 31, 2016​\n* PROMETIC LIFE SCIENCES - ‍RECEIVED FDA INVESTIGATIONAL NEW DRUG (IND) APPROVAL TO COMMENCE ITS PIVOTAL PHASE 3 CLINICAL TRIAL OF PBI-4050 DRUG ​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-29T09:11:00.000+03:00",
    "crawled": "2018-03-29T16:14:06.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "prometic",
        "life",
        "science",
        "inc",
        "prometic",
        "report",
        "financial",
        "result",
        "provides",
        "update",
        "activity",
        "revenue",
        "q4",
        "ended",
        "december",
        "million",
        "compared",
        "million",
        "q4",
        "ended",
        "december",
        "prometic",
        "life",
        "science",
        "fda",
        "investigational",
        "new",
        "drug",
        "ind",
        "approval",
        "commence",
        "pivotal",
        "phase",
        "clinical",
        "trial",
        "drug",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}